PLS Drug Trial Research
No drug has ever been approved for PLS. No PLS-specific drug trial has ever succeeded. These two facts have been true for as long as PLS has been recognized as a disease, and they will remain true for at least several more years. But the landscape in 2026 is more interesting than that flat summary suggests. The ALS drug pipeline is busier than it has ever been, and several agents now in late-stage development target biological mechanisms that matter as much in upper motor neurons as in lower ones. More importantly, a regulatory precedent was set in 2023 that changes what a future PLS trial could look like — and the natural history infrastructure to use that precedent is being built right now.
Why PLS has almost no dedicated trials
The structural barriers are real and interconnected. PLS affects perhaps 1,500 to 3,000 Americans — roughly 3% of the motor neuron disease population. Recruiting 100 or 200 patients into a randomized trial from that pool, across multiple centers, with enough follow-up time to detect a meaningful treatment effect in a slowly-progressing disease, is an enormous logistical and financial undertaking. Pharmaceutical sponsors with limited capital choose the larger, faster-moving disease.
The slowness itself compounds the problem. At an average rate of 1.6 to 2 ALSFRS-R points per year, detecting a 30% slowing of PLS progression with conventional clinical endpoints in a 12-month trial would require hundreds of patients — far beyond what any single PLS center could enroll. Without a sensitive biological endpoint that could detect a treatment effect before it registers on clinical scales, the math doesn't work for most commercial sponsors. The combination of small disease population, slow progression, and diagnostic uncertainty (the 2- and 4-year windows before "probable" and "definite" PLS can be assigned) has effectively locked PLS out of the trial ecosystem that ALS has developed over three decades.
Where the evidence comes from
The story of PLS drug development, such as it is, starts with riluzole — the drug that has been used off-label in PLS for decades while never being tested there. The original riluzole trials in ALS, published in the New England Journal of Medicine in 1994 and The Lancet in 1996, established that a glutamate antagonist could slow ALS progression modestly and became the template for every MND trial that followed. Riluzole has been given to PLS patients by neurologists who reasoned that glutamate excitotoxicity plausibly applies to upper motor neurons too. That reasoning may be correct — but no randomized trial has tested it in PLS, and the 2025 Scirocco review notes that no disease-modifying therapy of any kind has demonstrated efficacy in PLS. For now, riluzole in PLS remains extrapolation, not evidence.
The moment that changed what is possible for PLS trial design came in 2023, with the FDA's accelerated approval of tofersen for SOD1-ALS. The tofersen VALOR trial — a Phase 3 antisense oligonucleotide study — did not meet its primary clinical endpoint of functional decline. The FDA approved it anyway, on the basis of its ability to reduce plasma neurofilament light chain (NfL), accepting NfL as a surrogate endpoint for the first time in motor neuron disease. That regulatory precedent is the key that could unlock PLS trial design: if regulators will accept NfL reduction as approvable evidence in ALS, then a PLS trial using NfL as a primary endpoint — rather than clinical scales requiring years of follow-up — becomes conceptually tractable. The PLS Natural History Study's finding that baseline NfL predicts PLSFRS decline (p = 0.001) means that foundation is being built.
While tofersen is not relevant to PLS directly (it targets SOD1 mutations, which are rare in PLS), the MIROCALS trial is worth examining for what it demonstrated about trial design in MND. MIROCALS tested low-dose interleukin-2 as an immunomodulatory therapy in ALS — a mechanism that could matter in PLS, which involves neuroinflammation in the motor cortex. The trial missed its primary endpoint of survival and functional decline. But in a pre-specified subgroup stratified by baseline CSF pNfH — roughly 80% of participants with lower pNfH — active treatment was associated with a greater than 40% reduction in risk of death. The stratified result was not sufficient for approval, but it demonstrated two things the PLS field should absorb: that biomarker-based patient selection can reveal treatment effects invisible in an unselected population, and that immunomodulation in MND is not a closed door.
The HEALEY ALS Platform Trial at Massachusetts General Hospital introduced a different kind of innovation — not a specific drug, but a trial architecture. The platform model tests multiple drugs simultaneously in a shared patient pool, with a common control arm, using adaptive randomization to identify signals more efficiently than traditional parallel-group designs. Pridopidine's Phase 3 advancement came partly through HEALEY's infrastructure. For PLS, the platform model is particularly interesting: it could address the recruitment problem by pooling patients across multiple investigational arms, and the shared natural history data from the PNHS provides exactly the historical control data such a platform would need.
Among the agents now in Phase 2 and 3 that have the most direct conceptual relevance to PLS biology, two stand out. PrimeC, tested in the PARADIGM Phase 2b trial, is a fixed-dose combination of ciprofloxacin and celecoxib targeting neuroinflammation and RNA metabolism. In PARADIGM, patients on active treatment showed approximately 37.4% slower progression than historical controls, and the FDA authorized a Phase 3 program. PrimeC's anti-inflammatory mechanism is not ALS-specific; it targets pathways active in UMN degeneration generally, which is why PLS researchers are watching the Phase 3 data. SPG302, in Phase 2a, targets synaptic density — the number and health of synaptic connections on motor neurons. In its trial, treated patients showed 76% slower decline compared to historical controls. The mechanism is compelling for PLS specifically: upper motor neuron loss in PLS includes loss of corticospinal synaptic connections, and an agent that could maintain synapse density would be acting directly on the biology of UMN disease.
Pridopidine in the PREVAiLS Phase 3 trial represents the broadest neuroprotective approach currently in late-stage testing. A sigma-1 receptor agonist, pridopidine modulates calcium homeostasis, endoplasmic reticulum stress, and mitochondrial function — pathways relevant to motor neuron vulnerability across disease types. PREVAiLS launched in April 2026, enrolling early, rapidly-progressive ALS patients. PLS patients are not eligible, but the mechanism is broadly neuroprotective. If pridopidine shows efficacy in ALS, the case for testing it in PLS is straightforward.
Ravulizumab, tested in the ATLAS Phase 3 trial, represents a different mechanistic angle: complement inhibition. Neuroinflammation in ALS and PLS involves aberrant complement system activation, and ravulizumab (an anti-C5 antibody already approved in other complement-mediated diseases) was tested in ALS to evaluate whether complement inhibition slows motor neuron loss. ATLAS enrolled patients with rapidly-progressing ALS; results are pending as of early 2026. The complement pathway is active in PLS as well, and the ATLAS results will inform whether this mechanism warrants further investigation across the MND spectrum.
What we know — and what we don't
The honest current state is that PLS patients are watching the ALS drug pipeline with acute attention, because any drug that succeeds in ALS by targeting upper motor neuron-relevant biology opens the door to a PLS trial using the tofersen/NfL regulatory precedent. The chain of events that could eventually produce an approved PLS therapy runs roughly as follows: PrimeC or SPG302 shows meaningful slowing of ALS progression in a Phase 3 trial; the mechanism is recognized as UMN-relevant; the PNHS provides the NfL and PLSFRS validation data needed to design a PLS-specific trial; a trial is proposed using NfL as a primary endpoint; and regulators, having already accepted NfL as a surrogate in ALS, consider the same precedent for PLS.
That chain is not guaranteed. Each link could fail. But as of 2026, more links are in place than at any prior point in the history of PLS research. The natural history data exists. The outcome measure exists. The biomarker precedent exists. The missing element is a drug candidate with compelling Phase 2 evidence in UMN biology — and two of the trials described above are the closest candidates the field currently has.
Why it matters for you
If you have PLS and want to understand what research participation looks like, the most direct contribution right now is the PLS Natural History Study, which is not a drug trial but is the direct prerequisite for one. Every patient enrolled in the PNHS contributes to the progression benchmarks and biomarker validation that a future treatment trial will depend on. The clinical trials page has current enrollment information. The treatments page covers what is available now, including riluzole and symptomatic management.
Individual studies in this section
Full details on each study, including methods, findings, and context: